Efficacy of Cicatricort® in the Prevention of Keloids in Postoperative Plastic Surgery: A Retrospective Comparative Study (2023–2025)

Introduction: Keloid scars result from an exaggerated wound healing response characterized by excessive fibroblast proliferation and collagen deposition. Their formation is linked to persistent inflammation, dysregulated activation of growth factors such as TGF-β1, and imbalance between extracellular matrix synthesis and degradation. Due to the lack of effective preventive measures, this study evaluated the efficacy of Cicatricort a topical cream composed of acetylsalicylic acid, allantoin, vitamin E, and Sedum rosea root extract in preventing keloid formation in patients undergoing plastic surgeries, including otoplasty, macrotia correction, blepharoplasty, rhytidoplasty, mammoplasty, abdominoplasty, and gynecomastia surgery. Methods: A retrospective analysis was conducted with 13,728 patients undergoing plastic surgeries. They were divided into two groups: a control group (n = 6,864) using corticosteroid-based scar creams between March 2023 and April 2024, and an experimental group (n = 6,864) using Cicatricort for 90 days postoperatively from May 2024 to April 2025. Keloid incidence was assessed with a minimum follow-up of 24 months. Results: In the control group, 1.06% of patients developed keloids according to clinical records. In the Cicatricort group, no keloid formation was observed. These findings suggest a strong preventive effect of the formulation, inhibiting fibrotic and chronic inflammatory cellular processes. Conclusion: Cicatricort demonstrated significant efficacy in preventing keloid scars in plastic surgery patients by targeting key pathophysiological mechanisms of pathological scarring.